Publication:
Impact of individualized management of breakthrough cancer pain on quality of life in advanced cancer patients: CAVIDIOPAL study.

Simple item page
dc.contributor.authorTuca Rodríguez, Albert
dc.contributor.authorNúñez Viejo, Miguel
dc.contributor.authorMaradey, Pablo
dc.contributor.authorCanal-Sotelo, Jaume
dc.contributor.authorGuardia Mancilla, Plácido
dc.contributor.authorGutiérrez Rivero, Sonia
dc.contributor.authorRaja Casillas, Inmaculada
dc.contributor.authorHerrera Abián, María
dc.contributor.authorLópez Bermudo, Cristina
dc.date.accessioned2023-02-09T10:40:57Z
dc.date.available2023-02-09T10:40:57Z
dc.date.issued2021-02-03
dc.description.abstractThe main aim of the study was to assess the impact of individualized management of breakthrough cancer pain (BTcP) on quality of life (QoL) of patients with advanced cancer in clinical practice. A prospective, observational, multicenter study was conducted in patients with advanced cancer that were assisted by palliative care units. QoL was assessed with the EORTC QLQ-C30 questionnaire at baseline (V0) and after 28 days (V28) of individualized BTcP therapy. Data on background pain, BTcP, comorbidities, and frailty were also recorded. Ninety-three patients completed the study. Intensity, duration, and number of BTcP episodes were reduced (p  Individualized BTcP therapy improved QoL of patients with advanced cancer. Transmucosal fentanyl at low doses was the most used drug. This study was registered at ClinicalTrials.gov database (NCT02840500) on July 19, 2016.
dc.identifier.doi10.1007/s00520-021-06006-1
dc.identifier.essn1433-7339
dc.identifier.pmcPMC8236456
dc.identifier.pmid33533986
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236456/pdf
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s00520-021-06006-1.pdf
dc.identifier.urihttp://hdl.handle.net/10668/17091
dc.issue.number8
dc.journal.titleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
dc.journal.titleabbreviationSupport Care Cancer
dc.language.isoen
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number4799-4807
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectBreakthrough cancer pain
dc.subjectIndividualized therapy
dc.subjectPalliative care
dc.subjectQuality of life
dc.subjectTransmucosal fentanyl
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshBreakthrough Pain
dc.subject.meshCancer Pain
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasms
dc.subject.meshPain Management
dc.subject.meshProspective Studies
dc.subject.meshQuality of Life
dc.titleImpact of individualized management of breakthrough cancer pain on quality of life in advanced cancer patients: CAVIDIOPAL study.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number29
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PMC8236456.pdf
Size:
361.01 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario San Cecilio
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía